Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy

Jung Yun Lee, Kyunghoon Kim, Yun Shin Lee, Hyo Young Kim, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Jae Weon Kim, YoungTae Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background The GOG-218 and ICON-7 studies recently showed that adding bevacizumab to first-line therapy for patients with advanced ovarian cancer increased progression-free survival. However, the high cost and long treatment duration prevents the incorporation of bevacizumab in practice. The aim of this study was to explore and quantify patients’ preferences for adding bevacizumab to first-line therapy. Methods A discrete choice experiment (DCE) and trade-off question were designed and distributed to 102 ovarian cancer patients. Participants were asked to choose between two hypothetical first-line therapies that differed in terms of effectiveness, safety, and the financial burden. A trade-off technique varying the cost of bevacizumab was used to quantify a willingness-to-pay threshold for selecting bevacizumab. Results All attributes of the DCE had a statistically significant impact on respondents’ preferences and the financial burden was the most important attribute. The results of the trade-off question showed that more than half of patients would prefer to add bevacizumab to standard chemotherapy when the cost of the drug was reduced to 17% (1/6) of the baseline cost. Conclusion Patients’ preferences for bevacizumab in the adjuvant treatment of ovarian cancer depend primarily on drug costs. Our results suggest that the current cost of bevacizumab is sufficiently high that the majority of ovarian cancer patients are not willing to pay to accept a small increase in progression-free survival.

Original languageEnglish
Pages (from-to)622-627
Number of pages6
JournalGynecologic Oncology
Volume143
Issue number3
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Ovarian Neoplasms
Drug Costs
Patient Preference
Therapeutics
Costs and Cost Analysis
Disease-Free Survival
Bevacizumab
Health Care Costs
Safety
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Lee, Jung Yun ; Kim, Kyunghoon ; Lee, Yun Shin ; Kim, Hyo Young ; Nam, Eun Ji ; Kim, Sunghoon ; Kim, Sang Wun ; Kim, Jae Weon ; Kim, YoungTae. / Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. In: Gynecologic Oncology. 2016 ; Vol. 143, No. 3. pp. 622-627.
@article{0ae5aea6dbde46febab5b24775650a96,
title = "Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy",
abstract = "Background The GOG-218 and ICON-7 studies recently showed that adding bevacizumab to first-line therapy for patients with advanced ovarian cancer increased progression-free survival. However, the high cost and long treatment duration prevents the incorporation of bevacizumab in practice. The aim of this study was to explore and quantify patients’ preferences for adding bevacizumab to first-line therapy. Methods A discrete choice experiment (DCE) and trade-off question were designed and distributed to 102 ovarian cancer patients. Participants were asked to choose between two hypothetical first-line therapies that differed in terms of effectiveness, safety, and the financial burden. A trade-off technique varying the cost of bevacizumab was used to quantify a willingness-to-pay threshold for selecting bevacizumab. Results All attributes of the DCE had a statistically significant impact on respondents’ preferences and the financial burden was the most important attribute. The results of the trade-off question showed that more than half of patients would prefer to add bevacizumab to standard chemotherapy when the cost of the drug was reduced to 17{\%} (1/6) of the baseline cost. Conclusion Patients’ preferences for bevacizumab in the adjuvant treatment of ovarian cancer depend primarily on drug costs. Our results suggest that the current cost of bevacizumab is sufficiently high that the majority of ovarian cancer patients are not willing to pay to accept a small increase in progression-free survival.",
author = "Lee, {Jung Yun} and Kyunghoon Kim and Lee, {Yun Shin} and Kim, {Hyo Young} and Nam, {Eun Ji} and Sunghoon Kim and Kim, {Sang Wun} and Kim, {Jae Weon} and YoungTae Kim",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2016.10.021",
language = "English",
volume = "143",
pages = "622--627",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. / Lee, Jung Yun; Kim, Kyunghoon; Lee, Yun Shin; Kim, Hyo Young; Nam, Eun Ji; Kim, Sunghoon; Kim, Sang Wun; Kim, Jae Weon; Kim, YoungTae.

In: Gynecologic Oncology, Vol. 143, No. 3, 01.01.2016, p. 622-627.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy

AU - Lee, Jung Yun

AU - Kim, Kyunghoon

AU - Lee, Yun Shin

AU - Kim, Hyo Young

AU - Nam, Eun Ji

AU - Kim, Sunghoon

AU - Kim, Sang Wun

AU - Kim, Jae Weon

AU - Kim, YoungTae

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background The GOG-218 and ICON-7 studies recently showed that adding bevacizumab to first-line therapy for patients with advanced ovarian cancer increased progression-free survival. However, the high cost and long treatment duration prevents the incorporation of bevacizumab in practice. The aim of this study was to explore and quantify patients’ preferences for adding bevacizumab to first-line therapy. Methods A discrete choice experiment (DCE) and trade-off question were designed and distributed to 102 ovarian cancer patients. Participants were asked to choose between two hypothetical first-line therapies that differed in terms of effectiveness, safety, and the financial burden. A trade-off technique varying the cost of bevacizumab was used to quantify a willingness-to-pay threshold for selecting bevacizumab. Results All attributes of the DCE had a statistically significant impact on respondents’ preferences and the financial burden was the most important attribute. The results of the trade-off question showed that more than half of patients would prefer to add bevacizumab to standard chemotherapy when the cost of the drug was reduced to 17% (1/6) of the baseline cost. Conclusion Patients’ preferences for bevacizumab in the adjuvant treatment of ovarian cancer depend primarily on drug costs. Our results suggest that the current cost of bevacizumab is sufficiently high that the majority of ovarian cancer patients are not willing to pay to accept a small increase in progression-free survival.

AB - Background The GOG-218 and ICON-7 studies recently showed that adding bevacizumab to first-line therapy for patients with advanced ovarian cancer increased progression-free survival. However, the high cost and long treatment duration prevents the incorporation of bevacizumab in practice. The aim of this study was to explore and quantify patients’ preferences for adding bevacizumab to first-line therapy. Methods A discrete choice experiment (DCE) and trade-off question were designed and distributed to 102 ovarian cancer patients. Participants were asked to choose between two hypothetical first-line therapies that differed in terms of effectiveness, safety, and the financial burden. A trade-off technique varying the cost of bevacizumab was used to quantify a willingness-to-pay threshold for selecting bevacizumab. Results All attributes of the DCE had a statistically significant impact on respondents’ preferences and the financial burden was the most important attribute. The results of the trade-off question showed that more than half of patients would prefer to add bevacizumab to standard chemotherapy when the cost of the drug was reduced to 17% (1/6) of the baseline cost. Conclusion Patients’ preferences for bevacizumab in the adjuvant treatment of ovarian cancer depend primarily on drug costs. Our results suggest that the current cost of bevacizumab is sufficiently high that the majority of ovarian cancer patients are not willing to pay to accept a small increase in progression-free survival.

UR - http://www.scopus.com/inward/record.url?scp=84997766073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997766073&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.10.021

DO - 10.1016/j.ygyno.2016.10.021

M3 - Article

C2 - 27771167

AN - SCOPUS:84997766073

VL - 143

SP - 622

EP - 627

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -